Sunesis Pharmaceuticals Inc SNSS:NASDAQ (Common Stock)
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
|---|---|---|---|---|
| 1.43 | 0.08 5.93% | 4,445,549 | 6.4M |
Latest News Headlines for Sunesis Pharmaceuticals Inc
Sunesis Announces Results From Pivotal Phase 3 VALOR Trial of Vosaroxin and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia Trial Does Not Reach Primary Endpoint of Statistically Significant
Latest Annual and Quarterly SEC Filings
More FilingsCompany Background
Sunesis Pharmaceuticals, Inc. (Sunesis) is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The Company is focuses primarily on the development of vosaroxin for the treatment of acute myeloid leukemia (AML). Vosaroxin is a anti-cancer quinolone derivative (AQD). AQDs have been shown to mediate anti-tumor activity by targeting mammalian topoisomerase II, an enzyme critical for cell replication. The Company owns worldwide development and commercialization rights to vosaroxin. The Company's VALOR trial is designed to evaluate the effect of vosaroxin in combination with cytarabine, chemotherapy in AML. The trial has an adaptive design and is based on data from the Company's Phase II clinical trial of vosaroxin in combination with cytarabine in relapsed or refractory AML.
collapse, right-facing arrow indicating collapsed view of sectionOverview
| Bid | Size | -- | -- |
|---|---|
| Ask | Size | -- | -- |
| Price Open | 1.36 |
| Previous Close | 1.43 |
| Day High | -- |
| Day Low | -- |
| 52 Week High | 8/27/2014 | 8.455 |
| 52 Week Low | 10/8/2014 | 1.25 |
| % Off 52 Week High | (83.09)% |
| % Off 52 Week Low | 14.40% |
| Beta (5 Yr) | 2.6 |
| Volatility Avg | 10/8/2014 | 94.47 |
| 10-Day Avg. Volume | 6,356,657 |
| Market data is delayed by at least 20 minutes. | |
collapse, right-facing arrow indicating collapsed view of sectionFundamentals
| EPS (TTM) | 6/30/2014 | (0.73) |
|---|---|
| P/E Ratio | 6/30/2014 | -- |
| Market Cap | Micro Cap | 86M |
| Shares Outstanding | 60.44M |
| Float | 59.9M |
collapse, right-facing arrow indicating collapsed view of sectionDividends
| Dividend Yield | -- |
|---|---|
| Ex-Date | -- |
| Dividend Announcement | -- |
| Date of Record | -- |
| Payable | -- - -- |
| Payable Date | -- |
Peers Information HelpSNSS Sunesis Pharmaceuticals Inc vs. Peers
| Peers | |
|---|---|
SNSS Sunesis Pharmaceuticals Inc | -69.83% |
Johnson & Johnson | 14.54% |
Pfizer Inc. | -4.08% |
Merck & Co., Inc. | 20.24% |
Celgene Corporation | 12.32% |
SNSS Sunesis Pharmaceuticals Inc | 0.00% |
Johnson & Johnson | 2.67% |
Pfizer Inc. | 3.54% |
Merck & Co., Inc. | 2.92% |
Celgene Corporation | -- |
SNSS Sunesis Pharmaceuticals Inc | 5.93% |
Johnson & Johnson | 2.46% |
Pfizer Inc. | 2.05% |
Merck & Co., Inc. | 2.94% |
Celgene Corporation | 2.64% |